Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DeCode Genetics has submitted an investigational new drug application to the FDA for DG051, the company's follow-on investigational compound for the prevention of heart attack.
Subscribe to our email newsletter
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway DeCode has linked to risk of heart attack.
Like DG031, the company’s lead compound for the prevention of heart attack now in phase III clinical testing, DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4), an end product of the leukotriene pathway and a potent promoter of inflammation.
Pending clearance of the investigational new drug (IND) application by the FDA, DeCode expects to begin phase I clinical testing of the compound later this summer.